Literature DB >> 2875145

Undescended testis: the effect of treatment on subsequent risk of subfertility and malignancy.

C Chilvers, N E Dudley, M H Gough, M B Jackson, M C Pike.   

Abstract

The literature was reviewed for information on the long-term effects of cryptorchidism on fertility and cancer incidence. In unilateral cryptorchidism, treatment policies of orchidopexy alone, or of human chorionic gonadotrophin (hCG) therapy followed, if necessary, by orchidopexy, have resulted in similar levels of reduced fertility (15% azoospermia, and an additional 30% oligospermia, ie, sperm count less than 20 X 10(6)/mL). Very similar results were observed in unilateral cryptorchid men who had had no treatment (and were still cryptorchid at semen examination). In contrast, no untreated bilaterally cryptorchid men have normal fertility (sperm count greater than 20 X 10(6)/mL), whereas of those treated, a quarter have normal fertility. In some series, as many as half of the bilateral cryptorchid testes descended following hormonal treatment; a finding that could be attributed, at least in part, to the frequent difficulty in deciding on clinical examination, whether these testes are truly cryptorchid. There is little evidence that operation early rather than late within the age range of 4 to 14 years has any effect on subsequent fertility. Histologic studies suggest that orchidopexy should be carried out before age 2, but there are almost no follow-up data with which to evaluate the results of early operation. Since there is evidence that orchidopexy may result in testicular atrophy in a small proportion of cases, a trial of luteinizing hormone-releasing hormone (LHRH) may be advisable. There is little information available concerning the effect of age at orchidopexy on the subsequent risk of testicular cancer. Testes that cannot be brought into the scrotum should be excised.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875145     DOI: 10.1016/s0022-3468(86)80389-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  50 in total

1.  Management of the impalpable testis: the role of laparoscopy.

Authors:  C T Baillie; G Fearns; L Kitteringham; R R Turnock
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 2.  The genetic and phenotypic basis of infertility in men with pediatric urologic disorders.

Authors:  Michael H Hsieh; Adam Hollander; Dolores J Lamb; Paul J Turek
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

3.  Prevalence of late orchidopexy is consistent with some undescended testes being acquired.

Authors:  K M Donaldson; S Y Tong; J M Hutson
Journal:  Indian J Pediatr       Date:  1996 Nov-Dec       Impact factor: 1.967

4.  Preschool screening for cryptorchidism.

Authors:  S A Kaul; D P Roberts
Journal:  BMJ       Date:  1992-07-18

5.  Screening for undescended testes.

Authors:  D W Goh; J M Hutson
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

6.  Metachronous tumors of testis in undescendent and ectopic testis.

Authors:  I Ozbey; Y Aksoy; O Polat; C Gündoğdu; O Biçgi
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

7.  [Therapy of cryptorchidism. Viewpoints for optimizing fertility].

Authors:  B O Backhaus; S C Müller
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 8.  Physical deformities relevant to male infertility.

Authors:  Rajender Singh; Alaa J Hamada; Laura Bukavina; Ashok Agarwal
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

9.  Regional variations in testicular cancer rates in Ireland.

Authors:  M Alsinnawi; M R Quinlan; S Deady; E A Kiely
Journal:  Ir J Med Sci       Date:  2010-11-19       Impact factor: 1.568

10.  Evaluation of preoperative testicular volume in Japanese children with unilateral cryptorchidism.

Authors:  Hideyuki Kamisawa; Yoshiyuki Kojima; Yutaro Hayashi; Makoto Imura; Kentaro Mizuno; Kenjiro Kohri
Journal:  Int Urol Nephrol       Date:  2008-05-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.